Updated:
Tenpoint Therapeutics
Henric Bjarke leads Tenpoint Therapeutics, a Cambridge biotech pursuing pharmacological vision restoration for presbyopia, cataracts, and geographic atrophy.
Tenpoint Therapeutics
Discover how innovative eye treatments from Tenpoint Therapeutics™ may help restore lens clarity and rejuvenate vision in aging eyes.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Seattle
Corporate office
Seattle, WA, United States
Principals
Ben Bergo
President, Chief Business Officer
Henric Bjarke
Chief Executive Officer
Esther Cuno
Vice President of Human Resources
Melissa Epperly
Chief Financial Officer
Stephen S. Lane, MD
Chief Medical Officer
Tim Grinstead
Chief Operating Officer
Carol Kearney
Chief Commercial Officer
Yemisi Corinaldi
Vice President of Regulatory Affairs
David Guyer, MD
Chairman of the Board
John de Koning, PhD
Director
Eric D. Donnenfeld, MD
Director
Carmine Circelli
Director
Jim Mazzo
Director
Alexander Pasteur
Director
Graziano Seghezzi
Director
Tracy M. Valorie
Director
Zichao (Jason) Zhang
Director
Sector focus
Frequently asked questions
Does Tenpoint Therapeutics operate more like a biotech startup or a fully integrated pharma company?
Tenpoint markets itself as an integrated eye-care company — it is building its own commercial team under Chief Commercial Officer Carol Kearney rather than seeking an approval-and-partner pathway. This ambition places it between a development-stage biotech and a specialty-pharma operating company, with the attendant capital requirements. No disclosed funding rounds or revenue yet confirm its balance-sheet capacity to launch at scale.
What eye conditions beyond presbyopia does Tenpoint target?
The firm's pipeline includes programs for early cataract — aiming to restore lens clarity pharmacologically — and a cell-therapy program for geographic atrophy, the advanced form of dry age-related macular degeneration. Tenpoint frames these as a continuum of lens and retinal rejuvenation, though no clinical data or trial identifiers are publicly disclosed beyond the presbyopia NDA.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: